ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0901

Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence

Robert Moots1, Andy Cross2, Helen Wright2, Steven Edwards2, Nicola Goodson3, Jenny Hawkes3, Ayren Mediana1 and Helen Frankland1, 1Liverpool University Hospitals, Liverpool, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3University of Liverpool, Liverpool

Meeting: ACR Convergence 2020

Keywords: biologic response modifiers, neutrophils, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Secukinumab is a monoclonal antibody that neutralises IL-17A, which plays a key role in the IL-23/17A axis underlying the pathophysiology of psoriatic arthritis (PsA).  In this disease, Th17 cells produce IL-17A to trigger the release of chemoattractants such as CXCL8 and CCL20, leading to the infiltration of other immune cells including neutrophils. Activated neutrophils can themselves generate numerous chemokines and cytokines that can amplify and sustain inflammation.  Therapeutic targeting of IL-17 with biologics such as secukinumab in PsA may block this inflammatory cycle, but such inhibition should not have deleterious effects on other aspects of immunity associated with host defence.

This study measured changes in the functions of circulating neutrophils in PsA patients pre-therapy, compared to age- and sex-matched healthy controls, and determined if these functions changed in PsA patients prior to and during secukinumab therapy.

Methods: Neutrophils were isolated from venous blood of 20 PsA patients due to start secukinumab and 10 healthy controls. Key neutrophil functions such as: reactive oxygen species (ROS) production; phagocytosis; apoptosis (+/- TNF and GM-CSF); receptor expression and chemotaxis, were measured at baseline and 12 weeks.  Changes in gene expression pre- and 12-weeks post-therapy (n=5 PsA) were measured by RNAseq, and pre-treatment PsA neutrophil transcriptomes were also compared to healthy controls.

Results: There were no significant differences in ROS production, phagocytosis or chemotaxis in PsA patients at baseline (compared to healthy controls) or during therapy. RNA-seq analysis  revealed many genes with altered expression between PsA neutrophils at baseline and healthy controls.  For example, up-stream cytokines predicted to be regulating neutrophil gene expression in PsA included CSF2 (G-CSF), CD40LG, oncostatin M, interferons-a and -g, and TNFa. Ingenuity analysis revealed that signalling pathways associated with IL-8 signalling, toll-like receptor signalling and apoptosis signalling were among those significantly down-regulated by secukinumab. Of note, none of the patients treated with secukinumab contracted Covid-19.

Conclusion: Selective up- and down-regulation of neutrophil transcription was observed in PsA neutrophils compared to healthy controls, and in PSA neutrophils post treatment with secukinumab. However, while these changes may alter the pro-inflammatory function of neutrophils in PsA in response to IL-17A blockade, they did not adversely affect the ability of these neutrophils to carry out their role in host defence against infections.


Disclosure: R. Moots, Novartis, 2, 5; A. Cross, None; H. Wright, Novartis, 2; S. Edwards, Novartis, 2; N. Goodson, Novartis, 2, 8; J. Hawkes, None; A. Mediana, None; H. Frankland, None.

To cite this abstract in AMA style:

Moots R, Cross A, Wright H, Edwards S, Goodson N, Hawkes J, Mediana A, Frankland H. Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/proinflammatory-neutrophil-function-is-modulated-during-secukinumab-therapy-in-psoriatic-arthritis-without-compromising-host-defence/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proinflammatory-neutrophil-function-is-modulated-during-secukinumab-therapy-in-psoriatic-arthritis-without-compromising-host-defence/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology